First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Cancer Research and Clinical Oncology"
DOI: 10.1007/s00432-021-03893-z
Abstract: Osimertinib is still essential for the treatment of epidermal growth factor receptor (EGFR)-T790M-positive non-small-cell lung cancer (NSCLC) even in a relapsed setting, which suggests the importance of rebiopsy. The clinical value of repeat rebiopsy in… read more here.
Keywords: rebiopsy; lung; first rebiopsy; repeat rebiopsy ... See more keywords
Real-world data on efficacy and safety of osimertinib in non-small cell lung cancer patients with EGFR T790M mutation detected by first and repeat rebiopsy.
Sign Up to like & getrecommendations! Published in 2023 at "Asia-Pacific journal of clinical oncology"
DOI: 10.1111/ajco.13935
Abstract: BACKGROUND Osimertinib could effectively target epidermal growth factor receptor (EGFR) T790M resistance mutations in non-small cell lung cancer (NSCLC), indicating that rebiopsy may be particularly important. However, the clinical benefit of repeat rebiopsy in T790M-negative… read more here.
Keywords: osimertinib; t790m positive; repeat rebiopsy; rebiopsy ... See more keywords